Evidence map›Paper›PMID 28868617›Full record

ArticleThe Laryngoscope2018

Prophylactic immunization with human papillomavirus vaccines induces oral immunity in mice.

Julie Ahn, Shiwen Peng, Chien-Fu Hung, Richard B S Roden, Simon R Best

Open access · greenAbstract read
In one paragraph

Article in The Laryngoscope, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Julie AhnDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, U.S.A.
Shiwen PengDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, U.S.A.
Chien-Fu HungDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, U.S.A.
Richard B S RodenDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, U.S.A.
Simon R BestDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, U.S.A.ORCID 0000-0001-8699-033X
Johns Hopkins University · US

Funding

Therapeutic DNA vaccine for Recurrent Respiratory PapillomatosisK23DC014758 · NIDCD · JOHNS HOPKINS UNIVERSITY · PI BEST, SIMON R · 2016 to 2021
$1.0M
NIDCD NIH HHS K23 DC014758
6 · The paper itself

Abstract

objectiveAlthough it has been shown that prophylactic vaccination can induce genital immunity, there is inadequate information on human papillomavirus (HPV) vaccine-induced oral immunity, which is of particular interest due to HPV-associated oropharyngeal malignancies and recurrent respiratory papillomatosis. Therefore, we assessed the efficacy of various HPV vaccines against oral HPV pseudovirus (PsV) infection in mice. STUDY

designPreclinical scientific investigation.

methodsC57BL/6 mice were vaccinated three times at 2-week intervals with either Gardasil (Merck, Kenilworth, NJ) (50 µL intramuscular injection) or a candidate pan-HPV L2 vaccine with alum adjuvant (25 µg subcutaneous injection). Additional mice were immunized with passive transfer of either Gardasil (Merck) human antisera or nonimmunized sera (100 µL intraperitoneal injection). All vaccinated and naïve control mice were then challenged with HPV16 E6E7 luciferase PsV in the oral mucosa. Visualization of HPV PsV infection was monitored through in vivo luciferase imaging.

resultsOral luciferase-expressing HPV16 PsV infection was not detected in Gardasil (Merck), L2 vaccine, and Gardasil (Merck) antisera-immunized mice, whereas robust luciferase expression was observed in all control mice. An in vitro neutralization assay from sera of Gardasil-vaccinated (Merck) mice confirmed that vaccine efficacy was due to neutralizing antibodies.

conclusionOral HPV16 PsV infection in mice was completely prevented with all methods of prophylactic HPV immunization. These findings provide preliminary evidence that human vaccines induce protection against oral HPV infection, which has significant public health implications for HPV-associated oropharyngeal malignancies. LEVEL OF EVIDENCE: NA. Laryngoscope, 128:E16-E20, 2018.

Indexed as

AnimalsFemaleHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18HumansInjections, IntramuscularInjections, SubcutaneousLuciferasesMiceMice, Inbred C57BLOropharyngeal NeoplasmsPapillomavirus InfectionsPapillomavirus VaccinesRespiratory Tract InfectionsHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18LuciferasesPapillomavirus VaccinesHPVHuman papillomavirusoral HPVoral immunityvaccines

Identifiers

PMID28868617
PMCPMC5739972
OpenAlexW2555420684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.